MENU
TRVI
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Trevi Therapeutics (TRVI) Ownership - Who owns Trevi Therapeutics?
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis... Show more
Industry: #Pharmaceuticals Major
Profile
Industry
Pharmaceuticals Major
Address
195 Church Street
Phone
+1 203 304-2499
Employees
25
Web
https://www.trevitherapeutics.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
599.43M
P/E Ratio
N/A
Total Cash
107.62M
Projected Growth
N/A
Total Debt
1.03M
Revenue
N/A
Risk (Beta)
1.68
Dividend Yield
N/A
Total Cash/Share
1.11
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
TRVI
Capitalization
599M
P/E Ratio
N/A
Risk (Beta)
1.68
Dividend Yield
N/A
Total Cash
108M
Total Cash/Share
1.11
Total Debt
1.03M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
99.6M
P/B Ratio
6.02
Cash Flow
N/A
Earnings
-0.47
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
94K
Current Ratio
10.41
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-47.79M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-47.84
Shares Held By Institutions
315M
Shares Outstanding - Current
96.7M
Total Liabilities
11.3M
Total Volume MTD
N/A
Value
N/A
Gain YTD
50.485
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer and manufacturer of neurological products
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
195 Church Street
Phone
+1 203 304-2499
Employees
25
Web
https://www.trevitherapeutics.com